| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 06/17/2004 | US20040116432 Triazolo[4,3b]pyridazine as kinase inhibitors for treatment of cancerin mammals |
| 06/17/2004 | US20040116431 Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| 06/17/2004 | US20040116422 Drugs as enzyme inhibitors for tyrosine kinases and for treatment of psoriasis |
| 06/17/2004 | US20040116421 Heterocyclic compounds as antitumor agents with benzimidazole group and morpholine group, triazoline or pyrimidine heterocycles |
| 06/17/2004 | US20040116416 having immunomodulating and cytokine-release-inhibiting action |
| 06/17/2004 | US20040116407 therapy involving the use of pentamidine, or an analog of pentamidine, and chlorpromazine, or an analog of chlorpromazine |
| 06/17/2004 | US20040116400 Compounds, compositions, and methods |
| 06/17/2004 | US20040116393 Prevention of epithelial cancer |
| 06/17/2004 | US20040116369 Interferon regulatory factor-1/human estrogen receptor fusion protein and its use for treating carcinomas |
| 06/17/2004 | US20040116355 Caspase inhibitors and the use thereof |
| 06/17/2004 | US20040116354 Supplementary immunotherapeutics to be used after lung cancer removal |
| 06/17/2004 | US20040116342 Therapeutic use of a SMR1-peptide or a pharmaceutically active amount of SMR1-peptide, for the preparation of a therapeutic formulation for preventing or treating diseases wherein a modulation of activity of a membrane metallopeptidase is sought |
| 06/17/2004 | US20040116333 Administering to the individual a multimeric compound that binds to at least two P-Selectin Glycoprotein Ligand 1 (PSGL-1) proteins on the surface of a T cell to induces a signal transduction pathway that results in the death of the T cell |
| 06/17/2004 | US20040116330 Preventive/therapeutic method for cancer |
| 06/17/2004 | US20040116328 Condensed imidazole derivatives |
| 06/17/2004 | US20040115773 Serpin in bifidobacteria |
| 06/17/2004 | US20040115761 Polypeptides and nucleic acids encoding same |
| 06/17/2004 | US20040115667 Dna-sequences, which code for an apoptosis signal transduction protein |
| 06/17/2004 | US20040115656 Androgen receptor down-regulatory-associated proteins(ARDAPs) for use in reduction of transactivation activity of androgen receptors and treatment of tumors; gene expression inhibition and anticarcinogenic agents |
| 06/17/2004 | US20040115331 Suitable for inclusion in food |
| 06/17/2004 | US20040115283 Administering parenterally a therapeutically effective amount of one or more arsenic compounds |
| 06/17/2004 | US20040115243 Compositions for oral delivery of nutrients and pharmaceuticals |
| 06/17/2004 | US20040115221 Intracellular delivery vehicles |
| 06/17/2004 | US20040115212 Attenuated microorganism strains and their uses |
| 06/17/2004 | US20040115205 Use of antibodies against the MUC18 antigen |
| 06/17/2004 | US20040115202 monospecific antibody which specifically binds an epitope of a mammalian DPPIV (dipeptidyl peptidase IV, also known as CD26). |
| 06/17/2004 | US20040115193 Internalizing anti-CD-74 antibodies and methods of use |
| 06/17/2004 | US20040115186 a urease enzyme, and having associated with it a chemical entity effective to enhance the delivery of the enzyme to cancer cells |
| 06/17/2004 | US20040115129 Nucleic acid sequence 1 or 3; amino acid sequence 2 or 4 |
| 06/17/2004 | CA2508536A1 An exopolysaccharides delivery system for active molecules |
| 06/17/2004 | CA2508479A1 Compounds resistant to metabolic deactivation and methods of use |
| 06/17/2004 | CA2507763A1 Fused 1,3-dihydro-imidazole ring compounds |
| 06/17/2004 | CA2507641A1 Method of producing macrolide compound |
| 06/17/2004 | CA2507011A1 Phosphoantigens for regulating an immune response |
| 06/17/2004 | CA2506546A1 Kinase modulators |
| 06/17/2004 | CA2485957A1 Protease inhibitor |
| 06/17/2004 | CA2481489A1 Cysteine protease inhibitor |
| 06/17/2004 | CA2453387A1 Compositions and methods related to nitrotyrosine-containing compounds as antigenic agents |
| 06/16/2004 | EP1428891A1 Novel gene nedl-1 |
| 06/16/2004 | EP1428887A1 Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
| 06/16/2004 | EP1428877A1 Novel protein and dna thereof |
| 06/16/2004 | EP1428832A2 Peptide and O-glycan inhibitors of selectin mediated inflammation |
| 06/16/2004 | EP1428826A2 Crystal forms of cytostatics |
| 06/16/2004 | EP1428530A1 Tetrapeptide derivative crystals |
| 06/16/2004 | EP1428528A1 Synergistic combinations of dietary fiber and NSAIDs for the treatment of cancer |
| 06/16/2004 | EP1427857A2 Mid 4460, a human tyrosine phosphatase family member and uses therefor |
| 06/16/2004 | EP1427855A2 Method and reagents for identifying gene targets for treating breast cancer |
| 06/16/2004 | EP1427844A1 New assay for inhibitors of translocases |
| 06/16/2004 | EP1427842A2 Mid 9002, a human sulfatase family member and uses therefor |
| 06/16/2004 | EP1427841A2 Nucleic acid-associated proteins |
| 06/16/2004 | EP1427836A2 Pseudotyped retroviral vector system |
| 06/16/2004 | EP1427830A2 Bv8 NUCLEIC ACIDS AND POLYPEPTIDES WITH MITOGENIC ACTIVITY |
| 06/16/2004 | EP1427825A2 Cdna encoding the human alpha2 delta4 calcium channel subunit |
| 06/16/2004 | EP1427813A2 Method for dendritic cells-based immunotherapy of tumors using combination therapy |
| 06/16/2004 | EP1427754A1 Nucleic acid and polypeptide linked to breast cancer and uses therefor |
| 06/16/2004 | EP1427739A1 Targeted bisplatinum polyamines as pro-drugs: selective release of platinum |
| 06/16/2004 | EP1427730A1 Novel dihydropteridinones, method for producing the same and the use thereof as medicaments |
| 06/16/2004 | EP1427722A2 Pyrrole-type compounds, compositions, and methods for treating cancer, treating viral diseases and causing immunosuppression |
| 06/16/2004 | EP1427720A1 3-substituted-4-pyrimidone derivatives |
| 06/16/2004 | EP1427712A2 Dye-azide compounds for dual phototherapy |
| 06/16/2004 | EP1427709A1 3-substituted-4-pyrimidone derivatives |
| 06/16/2004 | EP1427708A1 Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
| 06/16/2004 | EP1427707A1 Substituted indazole compounds for the treatment of inflammation |
| 06/16/2004 | EP1427706A1 Substituted pyrazolo compounds for the treatment of inflammation |
| 06/16/2004 | EP1427457A1 Medical devices containing rapamycin analogs |
| 06/16/2004 | EP1427449A1 Anti-cancer agents comprising disintegrin genes and the treating methods |
| 06/16/2004 | EP1427447A1 Improved therapeutic protocols |
| 06/16/2004 | EP1427445A2 Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules |
| 06/16/2004 | EP1427441A2 Composite superimmunogen for bi-functional vaccine use for the treatment of illnesses associated with a stromal tissue disorder |
| 06/16/2004 | EP1427434A2 Anti-inflammatory agent |
| 06/16/2004 | EP1427433A1 Biodegradable implant comprising a polylactide polymer and a lh-rh analogue |
| 06/16/2004 | EP1427431A2 Bioadhesive compositions and methods for enhanced mucosal drug absorption |
| 06/16/2004 | EP1427430A2 Use of extracts of the genus cimicifuga as organoselective medicines for treating diseases of the genitourinary system caused by sex hormones |
| 06/16/2004 | EP1427427A1 Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect |
| 06/16/2004 | EP1427424A2 Lpa receptor agonists and antagonists and methods of use |
| 06/16/2004 | EP1427422A1 Use of tyrosine kinase inhibitors for whitening human skin and treating melanocyte dysfunction associated diseases |
| 06/16/2004 | EP1427421A1 2,4-disubstituted pyrimidinyl derivatives for use as anticancer agents |
| 06/16/2004 | EP1427420A1 Use of 4-pyridylmethylphthalazines for cancer treatment |
| 06/16/2004 | EP1427418A2 Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment |
| 06/16/2004 | EP1427416A2 3-glyoxlylamideindoles for treating cancer |
| 06/16/2004 | EP1427413A2 2-aroylimidazole compounds for treating cancer |
| 06/16/2004 | EP1427412A1 Methods of treating cytokine mediated diseases |
| 06/16/2004 | EP1427407A2 Fatty amine drug conjugates |
| 06/16/2004 | EP1427404A2 Treatment of glial tumors with glutamate antagonists |
| 06/16/2004 | EP1427403A2 Valproic acid and derivatives for the combination treatment of human cancers, tumor metastasis and minimal residual disease |
| 06/16/2004 | EP1427402A1 Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide |
| 06/16/2004 | EP1427396A1 Dosage forms having prolonged active ingredient release |
| 06/16/2004 | EP1427395A1 Stabilization of active agents by formulation into nanoparticulate form |
| 06/16/2004 | EP1427391A1 Vascular occlusion solid-phase agent with immobilised platelet binding agent |
| 06/16/2004 | EP1427383A1 Compositions and methods relating to prevention of chemotherapy-induced alopecia |
| 06/16/2004 | EP1427366A2 Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy |
| 06/16/2004 | EP1427326A2 Combination therapy for the treatment of cancer |
| 06/16/2004 | EP1427289A2 Pulsatile release compositions and methods for enhanced gastrointestinal drug absorption |
| 06/16/2004 | EP1351958B1 Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation |
| 06/16/2004 | EP1339719B1 Benzimidazole derivatives, preparation and therapeutic use thereof |
| 06/16/2004 | EP1315731B1 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives |
| 06/16/2004 | EP1268387B1 Specific salt forms of triphenylethylene derivatives as selective estrogen receptor modulators |
| 06/16/2004 | EP1263751B1 2-phenylpyran-4-one derivatives |
| 06/16/2004 | EP1257556B1 Thiazolopyrimidines and their use as modulators of chemokine receptor activity |
| 06/16/2004 | EP1255751B1 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b or v1b and v1a arginine-vasopressin receptors |